HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NSAID, Antihistamine Use More Affected By Copay Raise Than Other Rxs – Study

This article was originally published in The Tan Sheet

Executive Summary

Consumer spending on prescription non-steroidal anti-inflammatories and antihistamines decreased 45% and 44%, respectively, when insurance copays for the products doubled, according to a study published in the Journal of the American Medical Association May 19

You may also be interested in...

J&J’s Aciphex Feels The Burn As Rx PPI Market Growth Levels Off

Domestic sales of Johnson & Johnson's Rx proton pump inhibitor Aciphex (rabeprazole 20 mg) were negatively affected by the launch of Procter & Gamble's Prilosec OTC, providing another example of the sluggish growth of the prescription PPI market

Aventis “Contingency Plans” For Allegra Include Outlicensing

Aventis is considering outlicensing the antihistamine Allegra (fexofenadine) as a "contingency plan" in the event that the product loses its sole-source prescription-only status

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts